JP2018522579A - アクチビンＩＩ型受容体リガンドトラップを使用するβ−サラセミアのインビトロ細胞培養法 - Google Patents

アクチビンＩＩ型受容体リガンドトラップを使用するβ−サラセミアのインビトロ細胞培養法 Download PDF

Info

Publication number
JP2018522579A
JP2018522579A JP2018512825A JP2018512825A JP2018522579A JP 2018522579 A JP2018522579 A JP 2018522579A JP 2018512825 A JP2018512825 A JP 2018512825A JP 2018512825 A JP2018512825 A JP 2018512825A JP 2018522579 A JP2018522579 A JP 2018522579A
Authority
JP
Japan
Prior art keywords
seq
certain embodiments
levels
cell culture
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018512825A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522579A5 (enExample
Inventor
カッペリーニ マリア
カッペリーニ マリア
サング ヴィクトリア
サング ヴィクトリア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2018522579A publication Critical patent/JP2018522579A/ja
Publication of JP2018522579A5 publication Critical patent/JP2018522579A5/ja
Priority to JP2021158571A priority Critical patent/JP2022023072A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Optics & Photonics (AREA)
JP2018512825A 2015-05-20 2016-05-19 アクチビンＩＩ型受容体リガンドトラップを使用するβ−サラセミアのインビトロ細胞培養法 Pending JP2018522579A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021158571A JP2022023072A (ja) 2015-05-20 2021-09-29 アクチビンＩＩ型受容体リガンドトラップを使用するβ－サラセミアのインビトロ細胞培養法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562164367P 2015-05-20 2015-05-20
US62/164,367 2015-05-20
US201662320032P 2016-04-08 2016-04-08
US62/320,032 2016-04-08
PCT/US2016/033187 WO2016187378A1 (en) 2015-05-20 2016-05-19 In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021158571A Division JP2022023072A (ja) 2015-05-20 2021-09-29 アクチビンＩＩ型受容体リガンドトラップを使用するβ－サラセミアのインビトロ細胞培養法

Publications (2)

Publication Number Publication Date
JP2018522579A true JP2018522579A (ja) 2018-08-16
JP2018522579A5 JP2018522579A5 (enExample) 2019-06-27

Family

ID=57320751

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018512825A Pending JP2018522579A (ja) 2015-05-20 2016-05-19 アクチビンＩＩ型受容体リガンドトラップを使用するβ−サラセミアのインビトロ細胞培養法
JP2021158571A Pending JP2022023072A (ja) 2015-05-20 2021-09-29 アクチビンＩＩ型受容体リガンドトラップを使用するβ－サラセミアのインビトロ細胞培養法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021158571A Pending JP2022023072A (ja) 2015-05-20 2021-09-29 アクチビンＩＩ型受容体リガンドトラップを使用するβ－サラセミアのインビトロ細胞培養法

Country Status (8)

Country Link
US (2) US10548976B2 (enExample)
EP (2) EP4190805A3 (enExample)
JP (2) JP2018522579A (enExample)
CN (1) CN108350057A (enExample)
CA (1) CA2986432A1 (enExample)
HK (1) HK1252174A1 (enExample)
MA (1) MA42160A (enExample)
WO (1) WO2016187378A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020193857A (ja) * 2019-05-28 2020-12-03 学校法人 東洋大学 熱中症マーカー及びその利用
JP2023518260A (ja) * 2020-03-20 2023-04-28 ケロス セラピューティクス インコーポレイテッド アクチビン受容体ｉｉ型キメラ及びその使用方法
JP2023529278A (ja) * 2020-04-28 2023-07-10 アクセルロン ファーマ インコーポレイテッド Ａｃｔｒｉｉタンパク質および後毛細管性肺高血圧症の処置における使用
JP2023534143A (ja) * 2020-06-23 2023-08-08 アクセルロン ファーマ インコーポレイテッド 肺動脈性肺高血圧症（ｐａｈ）の処置のためのａｃｔｒｉｉタンパク質

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX366336B (es) 2012-11-02 2019-07-05 Celgene Corp Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
SMT202300166T1 (it) 2014-12-03 2023-07-20 Celgene Corp Antagonisti di attivina- actrii e usi per il trattamento di sindrome mielodisplastica
EP4190805A3 (en) 2015-05-20 2023-08-16 Celgene Corporation In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps
US11123430B2 (en) 2015-11-04 2021-09-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
EP3538123A4 (en) 2016-11-10 2020-10-14 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE IIA VARIANTS AND THEIR METHODS OF USE
EP3567096B1 (en) * 2017-01-06 2024-05-29 Evident Corporation Cell observation system
CA3082146A1 (en) 2017-11-09 2019-05-16 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
CN120399032A (zh) 2018-01-12 2025-08-01 科乐斯疗法公司 激活素受体iib型变体及其使用方法
EP3790572A4 (en) * 2018-05-09 2022-03-16 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
US20230270821A1 (en) * 2020-11-06 2023-08-31 Acceleron Pharma Inc. Formulations comprising actrii polypeptide variants

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014066486A2 (en) * 2012-10-24 2014-05-01 Celgene Corporation Biomarker for use in treating anemia

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2338405T3 (es) 1999-02-04 2010-05-07 Pluristem Ltd. Metodo y aparato para mantenimiento y expasion de celulas madre hemopoyeticas y/o celulas progenitoras.
AU1325102A (en) 2000-10-16 2002-04-29 Phylos Inc Protein scaffolds for antibody mimics and other binding proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
PT1390535E (pt) 2001-04-26 2010-10-04 Amgen Mountain View Inc Bibliotecas combinatórias de domínios monoméricos
ES2551852T3 (es) 2004-07-23 2015-11-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
WO2006055689A2 (en) 2004-11-16 2006-05-26 Avidia Research Institute Protein scaffolds and uses thereof
EA201692543A1 (ru) 2005-11-23 2017-08-31 Акселерон Фарма Инк. Антагонисты активина-actriia и их применение для стимулирования роста кости
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
EP2468291B1 (en) 2006-12-18 2017-11-22 Acceleron Pharma, Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
CA2677007A1 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
CA3039330C (en) 2007-02-09 2021-11-09 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth in cancer patients
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
US20100008918A1 (en) 2008-06-26 2010-01-14 Acceleron Pharma Inc. Methods for dosing an actriib antagonist and monitoring of treated patients
JP5922928B2 (ja) * 2008-08-14 2016-05-24 アクセルロン ファーマ， インコーポレイテッド 赤血球レベルを高めるためのｇｄｆトラップの使用
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
EP2387412A4 (en) 2009-01-13 2013-04-03 Acceleron Pharma Inc PROCESS FOR INCREASING THE ADIPONECTIN MIRROR
CN102482339B (zh) 2009-06-08 2015-06-17 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
ES2796121T3 (es) * 2009-08-13 2020-11-25 Acceleron Pharma Inc Uso combinado de trampas de GDF y activadores del receptor de la eritropoyetina para aumentar los niveles de glóbulos rojos
CA2773494A1 (en) 2009-09-09 2011-03-17 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof
CA2779472C (en) 2009-11-03 2021-03-16 Acceleron Pharma Inc. The use of a composition comprising an activin type iib receptor polypeptide in the treatment of fatty liver disease
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
CA2852683A1 (en) 2011-10-17 2013-04-25 Acceleron Pharma, Inc. Methods and compositions for treating ineffective erythropoiesis
CN104981250A (zh) 2012-10-24 2015-10-14 细胞基因公司 用于治疗贫血的方法
MX366336B (es) 2012-11-02 2019-07-05 Celgene Corp Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
JP6649895B2 (ja) 2014-04-18 2020-02-19 アクセルロン ファーマ， インコーポレイテッド 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法
AU2015274277B2 (en) 2014-06-13 2021-03-18 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
SMT202300166T1 (it) 2014-12-03 2023-07-20 Celgene Corp Antagonisti di attivina- actrii e usi per il trattamento di sindrome mielodisplastica
HK1251157A1 (zh) 2015-05-13 2019-01-25 细胞基因公司 使用ACTRII配体陷阱治疗β-地中海贫血
EP4190805A3 (en) 2015-05-20 2023-08-16 Celgene Corporation In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps
US11123430B2 (en) 2015-11-04 2021-09-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
CA3005975A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
AU2017296040C1 (en) 2016-07-15 2023-06-22 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
MX2019001043A (es) 2016-07-27 2019-09-26 Acceleron Pharma Inc Metodos y composiciones para el tratamiento de la mielofibrosis.
JP7496686B2 (ja) 2017-06-14 2024-06-07 セルジーン コーポレイション 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014066486A2 (en) * 2012-10-24 2014-05-01 Celgene Corporation Biomarker for use in treating anemia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRITISH JOURNAL OF HAEMATOLOGY, 2014. 165, 870-882, JPN6020018879, ISSN: 0004514489 *
EXPERIMENTAL HEMATOLOGY 2013;41:155-166, JPN6020018883, ISSN: 0004514490 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020193857A (ja) * 2019-05-28 2020-12-03 学校法人 東洋大学 熱中症マーカー及びその利用
JP7388679B2 (ja) 2019-05-28 2023-11-29 学校法人 東洋大学 熱中症マーカー及びその利用
JP2023518260A (ja) * 2020-03-20 2023-04-28 ケロス セラピューティクス インコーポレイテッド アクチビン受容体ｉｉ型キメラ及びその使用方法
JP2023529278A (ja) * 2020-04-28 2023-07-10 アクセルロン ファーマ インコーポレイテッド Ａｃｔｒｉｉタンパク質および後毛細管性肺高血圧症の処置における使用
JP2023534143A (ja) * 2020-06-23 2023-08-08 アクセルロン ファーマ インコーポレイテッド 肺動脈性肺高血圧症（ｐａｈ）の処置のためのａｃｔｒｉｉタンパク質

Also Published As

Publication number Publication date
CA2986432A1 (en) 2016-11-24
WO2016187378A1 (en) 2016-11-24
EP3298034A1 (en) 2018-03-28
HK1252174A1 (zh) 2019-05-17
EP4190805A3 (en) 2023-08-16
CN108350057A (zh) 2018-07-31
EP3298034A4 (en) 2019-02-13
US20180161426A1 (en) 2018-06-14
US20200101157A1 (en) 2020-04-02
EP4190805A2 (en) 2023-06-07
US10548976B2 (en) 2020-02-04
JP2022023072A (ja) 2022-02-07
MA42160A (fr) 2018-03-28

Similar Documents

Publication Publication Date Title
US20200101157A1 (en) Vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps
Hosui et al. Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-β and STAT3 activation
Ohgami et al. Cd36, a member of the class b scavenger receptor family, as a receptor for advanced glycation end products
Imani et al. Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon gamma: role in tissue remodeling.
JP6501362B2 (ja) エリスロフェロンおよびｅｒｆｅポリペプチドならびに鉄代謝を調節する方法
Covarrubias et al. Optimized protocols for isolation, fixation, and flow cytometric characterization of leukocytes in ischemic hearts
US20040072259A1 (en) Methods and products for manipulating hematopoietic stem cells
Owen et al. Monocyte adherence to fibronectin: role of CD11/CD18 integrins and relationship to other monocyte functions
Liu et al. Elevated cyclin E levels, inactive retinoblastoma protein, and suppression of the p27KIP1 inhibitor characterize early development of promyeloid cells into macrophages
Fox et al. Compound heterozygous c-Mpl mutations in a child with congenital amegakaryocytic thrombocytopenia: functional characterization and a review of the literature
US9375464B2 (en) HLA-G isoform for use in the treatment of a disease associated with bone resorption
Chakrabarti et al. Control of islet intercellular adhesion molecule-1 expression by interferon-α and hypoxia
Chauhan et al. Adrenomedullin 2/intermedin regulates HLA-G in human trophoblasts
US20120201792A1 (en) Methods and products for manipulating hematopoietic stem cells
US20110039791A1 (en) Acetylcholinesterase (ache)-derived peptide as an inducer of granulocytopoiesis, uses and methods thereof
JP6297552B2 (ja) Ｍｄｓの治療のための、ｃｄ９５シグナル伝達経路阻害剤
Socie Recent advances in paroxysmal nocturnal hemoglobinuria: from the biology to the clinic
WO2019099615A1 (en) Use of copeptin to modulate the immune response and hematopoiesis, and stimulate bone growth
JP2025519561A (ja) Ｇｐｃｒ阻害剤及びその使用
US8349559B2 (en) System and method for identifying erythropoietin-responsive genes
Shahcheraghi The pathophysiology of anti-Kell" hemolytic disease of newborn."
Han et al. Proliferative capacity of single isolated CD34+ hematopoietic stem/progenitor cells in paroxysmal nocturnal hemoglobinuria
Menon ROLES FOR AN EPO-RECEPTOR PY343-STAT5 SIGNALING AXIS IN STRESS ERYTHROPOIESIS
WO2020112642A1 (en) Improved methods of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate
Worthen TFR2, HFE, and HJV in the regulation of body iron homeostasis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190517

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200609

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210601

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210929

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20211012

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20211012

C27A Decision to dismiss

Free format text: JAPANESE INTERMEDIATE CODE: C2711

Effective date: 20211130

C032 Notice prior to dismissal

Free format text: JAPANESE INTERMEDIATE CODE: C032

Effective date: 20211221

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20211221